skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

We will discuss the industry trends by examining the pipeline by company, therapeutic area, disease, target and drug type, using data from Pharma Intelligence’s Phamaprojects. This report will focus on research and development as it is now, how it is changing and mutating, and where it has been headed during 2016 and will be in 2017.

 

It will be followed up by our annual supplement reviewing the New Active Substance launches for last year. 

 

Join Alex Shimmings, Executive Editor, Europe, Commercial, Scrip, Pink Sheet, In Vivo and Ian Lloyd, Senior Director, Pharmaprojects and Data Integration - Citeline as they will share insight on the following key areas:

 

  • Total pipeline size – the pharma forest is teeming with life
  • The 2017 pipeline by phase – Baby boom leads the way, but growth throughout the family
  • Top companies – Big beasts still dominate, but Novartis is the new king of the jungleTop therapies – Cancer’s herds spread further into the pharma habitat
  • Types of pipeline drugs – As biologicals proliferate, is the small molecule becoming a dinosaur?
  • Mechanisms and Targets – how to stay alive in a crowded ecosystem
  • Survival of the fittest – Darwinian forces mean pharma’s creatures must find their niches 

 

 

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: